Cannabidiol (CBD), a compound of the Cannabis Sativa
plant, has gained significant prominence in the last few years due to its
health and therapeutic benefits. A recent Forbes Health Survey revealed that
60% of American adults use CBD products. Reputable CBD from this site may
help to alleviate anxiety, treat epileptic seizures, manage chronic pain, and
reduce inflammation. Recently, CBD has been proposed as a potential treatment
for devastating COVID-19, two years after its debate without a cure. CBD has a
drug status following the approval of Epidiolex, a CBD-infused drug for
treating seizures. This article examines current research on CBD in treating
COVID-19 and its possible implications.
So far, 630 million people have contracted COVID-19, and
more than 6 million have succumbed. While a wide range of vaccines is available
for COVID-19, the virus is still spreading and wreaking havoc on nations,
businesses, and communities worldwide, especially third-world countries with
low access to vaccines. As a result, the need for alternative treatment is at
an all-time high.
Various studies supported by reputable research bodies
like the National Institute of General Medical Sciences and the National Center
for Advancing Translational Sciences have assessed the effect of CBD on
COVID-19, especially SARS-CoV-2. Severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) is among the coronavirus species infecting people, causing mild
to severe symptoms. Both human and animal trials have been evaluated to
determine the interactions of CBD with Covid-19.
Laboratory studies and health record analysis have
revealed promising results, affirming that CBD has protective properties
against SARS-CoV-2. An article published in Science
Advances confirmed that CBD lowers the risk for SARS-CoV-2 in humans. CBD
is an antiviral during the early stages of SARS-CoV-2 infection and protects
against an overactive immune system.
In another study, CBD impedes SARS-CoV-2 infection in
humans and mice. It does so by hindering SARS-CoV-2 replication in lung
epithelial cells and reversing the impact of the virus on gene transcription.
Typically, when you introduce the SARS-CoV-2 virus into the lung cells, they
replicate, increasing the severity of the disease. However, when you treat lung
cells with CBD before presenting the virus, it does not multiply. Mice given
CBD doses before exposure to the SARS-CoV-2 virus had a lower likelihood of
getting COVID-19 than those in the control group.
A review article published in the Cannabis and Cannabinoid Research examined the effectiveness of CBD
in managing inflammatory-related COVID-19 symptoms. It analyzed preclinical and
clinical trials in PubMed, CINAHL, and ClinicalTrials.gov. Leveraging CBD’s
anti-inflammatory and immunosuppressive elements, the survey showed that
administering 300mg of CBD to COVID-19 patients averted the development of
severe infection and lowered parenchymal lung damage, lessening patient
hospitalization chances. Although researchers are optimistic about CBD’s
ability to treat the inflammatory symptoms of COVID-19 patients, more clinical
studies are warranted.
Studies on the use of CBD for COVID-19 also assessed the
efficacy of other compounds of cannabis. Out of more than 100 compounds, only
CBD portrayed a protective effect. CBD combined with THC lowers the defensive
ability substantially.
Early research indicates that CBD can be used to prevent
COVID-19 in the future. However, more research and clinical studies are necessary
to prove its efficacy. Additionally, future studies should determine the best
CBD delivery methods for optimal outcomes. The need for more clinical trials,
instead of preclinical trials on animals, is increasing daily.
CBD as a potential preventative agent against SARS-CoV-2
has several advantages;
●
Wide
availability in online and offline stores
●
Nonpsychoactive
properties –CBD does not produce a high feeling like other cannabis components
like THC.
●
Numerous
means of digestion, including oral, nasal, and inhalation. You can take it in
the form of oil, tinctures, capsules, and gummies.
●
It
does not require administration in hospital settings –many people have hospital
phobias and are more likely to embrace a treatment option outside this setting.
●
It
has minor side effects –CBD is majorly well tolerated; it can cause dry mouth,
reduced appetite, and drowsiness.
CBD has two main limitations as a prophylactic for
COVID-19. First, numerous CBD formulations are available in the market with
varying quality, amounts of CBD, and pharmacokinetic properties. It can be
challenging to establish the best CBD with optimal outcomes for COVID-19. CBD’s
purity and composition are vital since other CBD components like THC reduce CBD
antiviral efficacy. Second, although CBD offers multiple administration forms,
vaping and smoking evoke concerns about potential lung damage.
It is fundamental to note that there’s no scientific
evidence proving that over-the-counter CBD products effectively prevent and
treat COVID-19. Also, CBD should never replace the current safety measures for
protecting against COVID-19, such as vaccination and masking. If CBD is
approved in the future, it will be used with the current safety measures to prevent
infections.